Linked Life Data

1832911

Source:http://linkedlifedata.com/resource/pubmed/id/1832911

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1991-10-30
pubmed:abstractText
In a retrospective study of 35 patients with stage III-IV ovarian cancer, the probability to reach a complete (CR) or partial remission (PR) was studied by comparing the initial level, half-life and normalisation time of CA-125 during chemotherapy. In 15 CR patients, pretreatment CA-125 level was lower (70 U/l, range 16-1500 U/l) than in 20 PR patients (800 U/l, range 60-9000 U/l). The median normalisation time (NT) was 6 weeks in CR (range 0.7-5.5 months) and 4 months in PR patients (range 1.2-9 months). Marker half-life was 12 days for the CR group (range 4.5-30 days) and 21 days for the PR group (range 5.5-39 days). Remission duration (r = 0.56) and log cell kill (r = 0.72) were correlated with survival. Combining initial tumour diameter, marker level and NT predicted CR in 87.5% and PR in 86%. Estimating log cell kill by combining marker half-life and doubling time gives more insight into tumour cell kinetics and individual survival.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
993-5
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
CA-125 in ovarian cancer: relation between half-life, doubling time and survival.
pubmed:affiliation
Department of Internal Medicine, University Hospital, Groningen, The Netherlands.
pubmed:publicationType
Journal Article